# Marianne Mertens

> Marianne Mertens is a seed investor at Apollo Health Ventures backing Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures)
- Total investments: 5
- Last investment: Nov 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/marianne-mertens-6a042a32

Marianne Mertens is a seed investor at Apollo Health Ventures focused on Biotechnology and Therapeutics. Partner

## Contacts

5 contacts available for Marianne Mertens: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/marianne-mertens-5aad?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Therapeutics | 3 | 60% |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |
| Product Research | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 60% |
| Series A | 1 | 20% |
| Series B | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 20% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |
| The Netherlands | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Scripta Therapeutics | Scripta Therapeutics operates as a bio-tech company, that delivers transformative therapeutics through cutting edge technology. | $12M | Seed | Nov 13, 2025 |  |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M | Series B | Feb 04, 2025 |  |
| Booster Therapeutics | Booster Therapeutics is a biotech business that regulates cellular homeostasis and develops treatments for age-related disorders. | $15M | Seed | Oct 10, 2024 |  |
| Cleara Biotech | Cleara is developing therapeutics to eliminate senescent cells. | $2.5M | Seed | Sep 22, 2022 |  |
| Auron Therapeutics | Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $48M | Series A | Jul 20, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 2 deals together
- [BrightEdge Fund](https://shizune.co/investors/profile/brightedge-fund) — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [DCVC Bio](https://shizune.co/investors/profile/dcvc-bio) — VC Fund, 2 deals together
- [Mubadala Capital Ventures](https://shizune.co/investors/profile/mubadala-ventures) — VC Fund, 2 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 2 deals together

## About Apollo Health Ventures

VC Fund · Berlin, Germany

Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, HeartDisease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.

5 contacts available at Apollo Health Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Alexandra Bause | Co-Founder, Investment Director and Head of VentureLabs | https://shizune.co/investors/profile/alexandra-bause |
| Jens Eckstein | Managing Partner | https://shizune.co/investors/profile/jens-eckstein |
| Marianne Mertens | Partner | — |
| Marianne Mertens | Partner | — |
| Nils Regge | Co-Founder and Managing Director | https://shizune.co/investors/profile/nils-regge |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Marianne Mertens invest in?

Marianne Mertens invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Marianne Mertens?

Public channels for Marianne Mertens include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Marianne Mertens last invest?

The most recent investment recorded for Marianne Mertens closed in Nov 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co